Mevacor ability to slow progression of atherosclerosis gains FDA approval on Feb. 8.
MERCK MEVACOR ABILITY TO SLOW ATHEROSCLEROSIS PROGRESSION gained FDA approval on Feb. 8, Merck announced Feb. 9. Mevacor (lovastatin) is the first HMG-CoA reductase inhibitor, lipid-lowering drug to gain approval for that indication. The approval was based on data from three large-scale clinical trials on atherosclerosis: the Canadian Coronary Atherosclerosis Intervention Trial, the Familial Atherosclerosis Treatment Study and the Monitored Atherosclerosis Regression Study.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth